Full Issue

Individual Articles - Sep/Oct 2021 - Volume 25, Number 5

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2021 Pg. 356	PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800> Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Sep/Oct 2021 Pg. 364-371	Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Author(s): Uttaro Elizabeth, Zhao Fang, Schweighardt Anne
Sep/Oct 2021 Pg. 372-377	Compounding Pearls--Wound Care: Drugs and Formulations for Dermal Healing, Part 3: The Roles of Nitric Oxide, Sildenafil, and Naltrexone Author(s): Riepl Mike
Sep/Oct 2021 Pg. 378-384	Realities of Pharmaceutical Compounding in the Republic of Uzbekistan Author(s): Umarov Ulugbek, Zdoryk Oleksandr, Kolisnyk Sergii, Fatkhullaeva Muyussar
Sep/Oct 2021 Pg. 386-387	It's Time for a New Philosophy Author(s): Brunner Scott
Sep/Oct 2021 Pg. 389-395	Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2 Author(s): Higgins Doral (Neal) O, Prudom Melanie J, Summers Amy
Sep/Oct 2021 Pg. 396-400	Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 403-408	Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 11: Particulate Issues --- Silicone Oil in Vials, Cartridges, and Syringes Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 410	Calculations Author(s): Stockton Shelly J
Sep/Oct 2021 Pg. 412	Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 413	Cilazapril 1-mg/mL in Ora-Blend Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 414	Clonidine 0.01-mg/mL in Ora-Blend Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 415	Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 416	Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 417	Haloperidol 0.5-mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 418	Imipramine Hydrochloride 5-mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 419	Mycophenolate Mofetil 50-mg/mL in Ora-Plus:Cherry Syrup Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 420	Sorafenib 20-mg/mL in Oil Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 421	Spironolactone 2-mg/mL or 2-5.mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 422-426	Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Author(s): Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli
Sep/Oct 2021 Pg. 427-430	Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base Author(s): Lopalco Antonio, Lopedota Angela, Aurelio Fiorenza, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Sep/Oct 2021 Pg. 431-439	Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A